Cardiff Oncology, Inc.CRDFNASDAQ
Loading
EPS Growth TrendStable
Percentile Rank57
5Y CAGR-14.5%
Studio
Year-over-Year Change

Year-over-year earnings per share growth rate

5Y CAGR
-14.5%/yr
Long-term compound
Percentile
P57
Within normal range
vs 5Y Ago
0.5x
Contraction
Streak
3 yr
Consecutive growthStable
PeriodValue
202527.37%
2024-2.15%
2023-4.49%
2022-21.92%
202132.41%
202060.00%
201961.76%
201886.35%
201744.72%
2016-23.91%